Why is Lushang Freda Pharmaceutical Co., Ltd. ?
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of -16.40% and Operating profit at -12.77% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 9.84% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of -16.40% and Operating profit at -12.77% over the last 5 years
3
Negative results in Mar 25
- OPERATING CASH FLOW(Y) Lowest at CNY 229.02 MM
- NET SALES(Q) Lowest at CNY 866.99 MM
- OPERATING PROFIT(Q) Lowest at CNY 41.54 MM
4
With ROE of 5.87%, it has a very expensive valuation with a 1.83 Price to Book Value
- Over the past year, while the stock has generated a return of 2.36%, its profits have fallen by -20%
5
Underperformed the market in the last 1 year
- The stock has generated a return of 2.36% in the last 1 year, much lower than market (China Shanghai Composite) returns of 14.77%
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Realty)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Lushang Freda Pharmaceutical Co., Ltd. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Lushang Freda Pharmaceutical Co., Ltd.
2.36%
-0.10
36.75%
China Shanghai Composite
14.77%
1.01
14.58%
Quality key factors
Factor
Value
Sales Growth (5y)
-16.40%
EBIT Growth (5y)
-12.77%
EBIT to Interest (avg)
4.65
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
17.48%
Dividend Payout Ratio
45.91%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.45%
ROE (avg)
9.84%
Valuation Key Factors 
Factor
Value
P/E Ratio
31
Industry P/E
Price to Book Value
1.83
EV to EBIT
23.24
EV to EBITDA
15.14
EV to Capital Employed
3.36
EV to Sales
1.25
PEG Ratio
NA
Dividend Yield
1.47%
ROCE (Latest)
14.48%
ROE (Latest)
5.87%
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Technical Movement
2What is working for the Company
RAW MATERIAL COST(Y)
Fallen by -3.56% (YoY
INVENTORY TURNOVER RATIO(HY)
Highest at 3.59%
-8What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at CNY 229.02 MM
NET SALES(Q)
Lowest at CNY 866.99 MM
OPERATING PROFIT(Q)
Lowest at CNY 41.54 MM
OPERATING PROFIT MARGIN(Q)
Lowest at 4.79 %
Here's what is working for Lushang Freda Pharmaceutical Co., Ltd.
Inventory Turnover Ratio
Highest at 3.59%
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Raw Material Cost
Fallen by -3.56% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Lushang Freda Pharmaceutical Co., Ltd.
Operating Cash Flow
Lowest at CNY 229.02 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (CNY MM)
Net Sales
At CNY 866.99 MM has Fallen at -12.04%
over average net sales of the previous four periods of CNY 985.61 MMMOJO Watch
Near term sales trend is very negative
Net Sales (CNY MM)
Net Sales
Lowest at CNY 866.99 MM
in the last five periodsMOJO Watch
Near term sales trend is negative
Net Sales (CNY MM)
Operating Profit
Lowest at CNY 41.54 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (CNY MM)
Operating Profit Margin
Lowest at 4.79 %
in the last five periodsMOJO Watch
Company's profit margin has deteriorated
Operating Profit to Sales






